Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

War on C Difficile Is Being Fought On Multiple Fronts

Executive Summary

Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.

You may also be interested in...



Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

Company’s Phase III program is attempting to replicate Phase II efficacy data showing superiority for curing Clostridium difficile infections and preventing recurrence, while also compiling health economics data.

Lyme Disease Vaccine Pushes Valneva To US Listing

Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.

Full Steam Ahead At Ferring To Unlock Microbiome Potential For Reproduction

The Swiss group is expanding its alliance with the Karolinska Institutet to conduct 10 studies designed to improve understanding of the microbiome’s impact on reproductive and gut health challenges.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS125410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel